Physician profile
John E Melba
NPI 1649229923
$10,770.84
in general payments reported to CMS, 2019-2025
58 companies · $1,840 in 2025
The $1,840 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,301 · 2020: $836 · 2021: $1,104 · 2022: $1,702 · 2023: $2,141 · 2024: $1,847 · 2025: $1,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,828.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,790.82 | 2019-2025 | |
| Novo Nordisk INC | $1,177.46 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $719.65 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $641.10 | 2020-2025 | |
| Lilly USA, LLC | $529.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $459.75 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Astrazeneca Pharmaceuticals Lp | $453.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $426.84 | 2021-2025 | |
| Astellas Pharma US INC | $360.89 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $317.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $310.73 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $296.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.81 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lundbeck LLC | $279.77 | 2022-2025 | Vyepti |
| Janssen Pharmaceuticals, INC | $224.43 | 2022-2025 | Spravato |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Melba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.